相似文献
1
A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.
Cancer Cell. 2014 Jan 13;25(1):77-90. doi: 10.1016/j.ccr.2013.12.009.
2
Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress.
Mol Cancer Ther. 2014 Nov;13(11):2537-46. doi: 10.1158/1535-7163.MCT-14-0256. Epub 2014 Oct 2.
3
Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors.
J Med Chem. 2014 Jun 12;57(11):4950-61. doi: 10.1021/jm5004842. Epub 2014 May 30.
4
Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
Prostate. 2019 Dec;79(16):1837-1851. doi: 10.1002/pros.23909. Epub 2019 Sep 16.
5
Targeting RNA polymerase I transcription machinery in cancer cells by a novel monofunctional platinum-based agent.
Eur J Med Chem. 2018 Jul 15;155:434-444. doi: 10.1016/j.ejmech.2018.05.045. Epub 2018 Jun 1.
6
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Cancer Res. 2011 Feb 15;71(4):1418-30. doi: 10.1158/0008-5472.CAN-10-1728. Epub 2010 Dec 15.
7
Targeting ribosomal G-quadruplexes with naphthalene-diimides as RNA polymerase I inhibitors for colorectal cancer treatment.
Cell Chem Biol. 2021 Nov 18;28(11):1590-1601.e4. doi: 10.1016/j.chembiol.2021.05.021. Epub 2021 Jun 23.
8
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Org Biomol Chem. 2019 Jan 16;17(3):683-691. doi: 10.1039/c8ob02668h.
9
Expression of RNA polymerase I catalytic core is influenced by RPA12.
PLoS One. 2023 May 11;18(5):e0285660. doi: 10.1371/journal.pone.0285660. eCollection 2023.
10
Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.
Mol Cancer Ther. 2016 Oct;15(10):2399-2412. doi: 10.1158/1535-7163.MCT-16-0172. Epub 2016 Sep 14.
引用本文的文献
1
Hypoxic stress incites HIF1α-driven ribosome biogenesis that can be exploited by targeting RNA Polymerase I.
Nat Commun. 2025 Aug 27;16(1):8018. doi: 10.1038/s41467-025-63315-3.
2
Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain.
J Transl Med. 2025 Aug 14;23(1):912. doi: 10.1186/s12967-025-06929-x.
3
Precise mapping of single-stranded DNA breaks by sequence-templated erroneous DNA polymerase end-labelling.
Nat Commun. 2025 Aug 4;16(1):7130. doi: 10.1038/s41467-025-62512-4.
4
Anticancer drug development against ribosome synthesis and the nucleolus.
Biochem Soc Trans. 2025 Aug 4. doi: 10.1042/BST20253011.
5
Elevated NPM1 and FBL expression correlates with prostate cancer aggressiveness and progression.
J Pathol. 2025 Sep;267(1):56-68. doi: 10.1002/path.6447. Epub 2025 Jul 24.
6
Ribosomal RNA transcription regulates splicing through ribosomal protein RPL22.
Cell Chem Biol. 2025 Jul 17;32(7):908-925.e9. doi: 10.1016/j.chembiol.2025.05.012. Epub 2025 Jun 18.
7
Bypassing the guardian: regulated cell death pathways in p53-mutant cancers.
Cell Mol Biol Lett. 2025 Jun 14;30(1):68. doi: 10.1186/s11658-025-00751-5.
8
4(3)-Quinazolinone: A Natural Scaffold for Drug and Agrochemical Discovery.
Int J Mol Sci. 2025 Mar 10;26(6):2473. doi: 10.3390/ijms26062473.
9
The natural alkaloid nitidine chloride targets RNA polymerase I to inhibit ribosome biogenesis and repress cancer cell growth.
Cell Death Discov. 2025 Mar 22;11(1):116. doi: 10.1038/s41420-025-02396-x.
10
Inhibition of Ribosome Biogenesis In Vivo Causes p53-Dependent Death and p53-Independent Dysfunction.
Cell Mol Gastroenterol Hepatol. 2025;19(7):101496. doi: 10.1016/j.jcmgh.2025.101496. Epub 2025 Mar 11.
本文引用的文献
1
Dysregulation of the basal RNA polymerase transcription apparatus in cancer.
Nat Rev Cancer. 2013 May;13(5):299-314. doi: 10.1038/nrc3496.
2
Cancer genome landscapes.
Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.
3
Ubiquitylation and degradation of elongating RNA polymerase II: the last resort.
Biochim Biophys Acta. 2013 Jan;1829(1):151-7. doi: 10.1016/j.bbagrm.2012.08.002. Epub 2012 Aug 31.
4
A conserved deubiquitinating enzyme controls cell growth by regulating RNA polymerase I stability.
Cell Rep. 2012 Aug 30;2(2):372-85. doi: 10.1016/j.celrep.2012.07.009. Epub 2012 Aug 16.
5
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Cancer Cell. 2012 Jul 10;22(1):51-65. doi: 10.1016/j.ccr.2012.05.019.
6
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
Sci Signal. 2011 Aug 30;4(188):ra56. doi: 10.1126/scisignal.2001754.
7
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
Sci Transl Med. 2011 Aug 10;3(95):95ra74. doi: 10.1126/scitranslmed.3002530.
8
Quantitative proteomics and dynamic imaging of the nucleolus reveal distinct responses to UV and ionizing radiation.
Mol Cell Proteomics. 2011 Oct;10(10):M111.009241. doi: 10.1074/mcp.M111.009241. Epub 2011 Jul 21.
9
Establishment and maintenance of alternative chromatin states at a multicopy gene locus.
Cell. 2011 May 13;145(4):543-54. doi: 10.1016/j.cell.2011.03.051.
10
Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes.
Cancer Res. 2011 Jun 15;71(12):4269-79. doi: 10.1158/0008-5472.CAN-10-3504. Epub 2011 May 9.
Zotero 插件